Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.

Ítems similars

• Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
  per: Generali, D, et al.
  Publicat: (2008)
• Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
  per: Fox, S, et al.
  Publicat: (2006)
• The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
  per: Fox, S, et al.
  Publicat: (2011)
• The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
  per: Fox, S, et al.
  Publicat: (2011)
• Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
  per: Mele, T, et al.
  Publicat: (2010)